Search results
Results from the WOW.Com Content Network
Nimodipine, sold under the brand name Nimotop among others, is a calcium channel blocker used in preventing vasospasm secondary to subarachnoid hemorrhage (a form of cerebral hemorrhage). It was originally developed within the calcium channel blocker class as it was used for the treatment of high blood pressure, but is not used for this indication.
Intracerebral hemorrhage (ICH), also known as hemorrhagic stroke, is a sudden bleeding into the tissues of the brain (i.e. the parenchyma), into its ventricles, or into both. [3] [4] [1] An ICH is a type of bleeding within the skull and one kind of stroke (ischemic stroke being the other).
Instead, it is most commonly associated with hemorrhage of small vessels in the cerebral cortex. [2] The strongest risk factor for intraparenchymal hemorrhage associated with cerebral amyloid angiopathy is old age, and cerebral amyloid angiopathy is most frequently seen in patients who already have, or will soon be diagnosed with, dementia. [3]
The most common cause of a subarachnoid hemorrhage is an aneurysm rupture due to the weakened blood vessel walls and increased wall stress. [48] The neurologic symptoms are produced by the blood mass effect on neural structures, from the toxic effects of blood on the brain tissue, or by the increasing of intracranial pressure. [49]
Brain ischemia has been linked to a variety of diseases or abnormalities. Individuals with sickle cell anemia, compressed blood vessels, ventricular tachycardia, plaque buildup in the arteries, blood clots, extremely low blood pressure as a result of heart attack, and congenital heart defects have a higher predisposition to brain ischemia in comparison to the average population.
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...
Certain drug interactions increase the risk of rare but serious side effects like increased bleeding and serotonin syndrome, a serious condition with symptoms of nausea, muscle twitching, tremor ...
[2] [3] The catheter is typically inserted on the right side of the brain, but in some cases a left-sided approach is used, and in other situations catheters are needed on both sides. [3] EVDs can be used to monitor intracranial pressure in patients with traumatic brain injury (TBI), [ 4 ] subarachnoid hemorrhage (SAH), [ 5 ] intracerebral ...